![]() |
|||||||||||||
View this email in a browser | |||||||||||||
![]() |
|||||||||||||
Over the last 20+ years, the devices available to deliver insulin have undergone enormous advancement, and the innovation and technology will continue at a faster pace than ever before. This wide cadre of insulin delivery devices that run the gamut from a simple patch to inhaled insulin to automated insulin delivery devices, can be used by people who take insulin, including people with type 1 diabetes, type 2 diabetes, and even women with gestational diabetes if they need insulin.
Registered dietitians and others involved with caring for and counseling people who take insulin should be aware of the selection of devices and know how to keep abreast of the technological evolution. RDs should also have a basic comprehension of how the FDA reviews these devices and ways that FDA has expanded regulatory pathways for innovation and approval. On Thursday, November 3, 2022, from 2-3 p.m. join Hope Warshaw, MMSc, RD, CDCES, BC-ADM, FADCES, as she delves into how these technologies can help RDs and their clinicians overcome common insulin delivery and diabetes management challenges. Hope will also provide a glimpse of what’s to come in the future of insulin delivery device technology. This webinar will allow RDs the opportunity to learn how to discuss these devices with clients and support their decision-making process based on clients’ individual needs and desires. Learning Objectives
|
|||||||||||||
|
|||||||||||||
|
|||||||||||||
About Our Presenter
|
|||||||||||||
Disclosures Hope Warshaw, MMSc, RD, CDCES, BC-ADM, FADCES, faculty for this event, has the following relevant financial relationship(s) with ineligible companies: she is a consultant to Insulet Corporation and LifeScan Diabetes Institute, and a trainer for Salute Nutrition, PLLC. She also participates as an advisory board member for Medtronic. All relevant financial relationships listed for this individual have been mitigated. The planners for this educational activity have no relevant financial relationship(s) with ineligible companies to disclose. An “ineligible company” includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products use by or on patients. |
|||||||||||||
Joint Accreditation Statement:
This activity will also award credit for dietetics (CDR CPEU). Dietitians: 1.0 CDR RDs and DTRs are to select activity type 102 in their Activity Log. Sphere and Competency selection is at the learner’s discretion. |